The Next Evolution in Clinical Decision Making and Patient Workflow

More than five million scans from thousands of healthcare professionals around the world have been analyzed. And that’s just the beginning of how we are continuing to redefine neurovascular and vascular patient care.


The Story of RapidAI

For 20+ years, most believed we had only a few hours after a stroke to provide treatment—but we were never satisfied with that thinking. We theorized that stroke evolution was highly variable, the conventional short treatment windows could be upended, and far more people with cerebrovascular disorders could be saved. We recognized that technology was the limiting factor even after an early NIH-funded, multicenter trial showed important advancements. We developed RAPID® (Rapid Processing of Perfusion and Diffusion) to address this need. Fast forward to today...

As the leader in brain imaging analysis, we are delivering proven software tools healthcare professionals around the world use to successfully identify and diagnose more cerebrovascular disorders than ever before possible. And now we are leveraging our experience and our clinical and technological expertise to extend our platform to other vascular conditions, offering hospitals even greater capabilities and opportunities to improve patient outcomes for life-threatening conditions. We take great pride in the role we continue to play in advancing patient care and helping healthcare professionals save lives, save time and save money.

Meet our team of innovators.

An experienced group of neurologists, radiologists, technologists and serial entrepreneurs.
Leadership Team

The Only Validated and Clinically Proven Solution

RapidAI Validation

Rapid for Stroke:
The Only Validated and Clinically Proven Solution

RapidAI Validation
Timeline of Events

RapidAI Evolution Through The Years


Dr. Greg Albers and Dr. Roland Bammer develop Rapid technology, the first fully automated image processing platform, at Stanford University with software engineer Matus Straka and funding from Sequoia Capital founder Don Valentine.

Rapid MRI software installed in eight US and one European center for the NIH-sponsored DEFUSE 2 study.

Dr. Albers and Dr. Bammer co-found the company iSchemaView (now named RapidAI®) and purchase the rights to Rapid technology from Stanford University.

The DEFUSE 2 study shows that by using Rapid MRI, physicians can identify stroke patients who respond favorably to endovascular clot removal up to 12 hours after stroke onset. Since then, RapidAI technology has been validated in more than a dozen multicenter clinical trials. (The recommended treatment window has since been extended to 24 hours.)

Rapid CTP developed and installed in more than 70 North American and European sites for the SWIFT PRIME, EXTEND, and EXTEND-IA trials.

Rapid CTP and Rapid MRI receive FDA clearance, allowing the platform to be used in hospitals throughout the U.S.

SWIFT PRIME and EXTEND-IA trials document the highest favorable outcome rates ever obtained in a stroke trial and validate the use of Rapid CTP to select patients for thrombectomy within 6 hours of symptom onset.

American Heart Association guidelines endorse thrombectomy as a new standard of care for stroke patients who can be treated up to 6 hours after onset. Rapid platform installed in more than 100 stroke centers.

Rapid platform selected as the exclusive imaging selection method for the late-window trials, DAWN and DEFUSE 3.

The Rapid platform achieves CE Mark certification, paving the way for use in the European Union.

Based on the DAWN and DEFUSE 3 clinical trials that used Rapid imaging to select stroke patients for late-window treatment, the American Heart and American Stroke associations revise guidelines, extending the treatment window for acute stroke patients from 6 to 24 hours.

The Rapid platform is approved for use in Canada, Australia, and New Zealand. Don Listwin is named CEO. Rapid ASPECTS announced, provides automated scoring to assess early signs of brain infarction. Rapid CTA receives FDA clearance.

The EXTEND trial doubles the treatment window for intravenous tPA using Rapid CTP and Rapid MRI.

Rapid CTA receives CE approval, becoming the first advanced imaging product indicated for localization of a detected large vessel occlusion (LVO).

Mexico, Brazil, Japan, Israel, and Vietnam join the list of 50+ countries that approve the use of Rapid platform.


Rapid ICH launches worldwide, using artificial intelligence to quickly notify physicians of possible intracranial hemorrhage.

RapidAI acquires Endovantage, an innovator in comprehensive aneurysm management—expanding scope from stroke to aneurysm.

RapidAI Insights launches—offering a suite of reports and analytics on Rapid scan, treatment, and outcomes data.

AI-powered Rapid ASPECTS becomes the first ever neuroimaging solution to receive FDA clearance in the CADx (Computer-Assisted Diagnostic software) category.


RapidAI hits a major milestone with over 1 million recorded scans and is used in 1,600+ hospitals worldwide.

Rapid LVO receives FDA clearance for identification of suspected large vessel occlusions.

RapidAI receives $25 million in Series B funding to accelerate the company’s strategic growth initiatives and expand AI-enhanced cerebrovascular imaging around the world.

RapidAI grows its global footprint to over 100 countries with its technology utilized in more than 1,800 hospitals.

RapidAI announces a new partnership with Penumbra to develop solutions to enable faster clinical decision-making for pulmonary embolism (PE) diagnosis and procedures.

RapidAI is named the exclusive advanced neuroimaging partner for the World Stroke Organization and SIECV stroke center certification program in Latin America.

Empowering Physicians to Push Boundaries for Improved Patient Outcomes

Machine learning and other artificial intelligence (AI) techniques are changing medicine in profound ways. At RapidAI, we are using it to extract greater meaning from medical imaging data and to develop tools that ultimately help physicians improve patient care.